MX2017006655A - Metodos y composiciones que comprenden desmopresina en combinacion con un antagonista del receptor alfa-adrenergico. - Google Patents
Metodos y composiciones que comprenden desmopresina en combinacion con un antagonista del receptor alfa-adrenergico.Info
- Publication number
- MX2017006655A MX2017006655A MX2017006655A MX2017006655A MX2017006655A MX 2017006655 A MX2017006655 A MX 2017006655A MX 2017006655 A MX2017006655 A MX 2017006655A MX 2017006655 A MX2017006655 A MX 2017006655A MX 2017006655 A MX2017006655 A MX 2017006655A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- desmopressin
- alpha
- combination
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 title abstract 2
- 239000000674 adrenergic antagonist Substances 0.000 title abstract 2
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 title abstract 2
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 title abstract 2
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 title abstract 2
- 229960004281 desmopressin Drugs 0.000 title abstract 2
- 206010036018 Pollakiuria Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010029446 nocturia Diseases 0.000 abstract 1
- 208000022934 urinary frequency Diseases 0.000 abstract 1
- 230000036318 urination frequency Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/745—Polymers of hydrocarbons
- A61K31/75—Polymers of hydrocarbons of ethene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Steroid Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462082301P | 2014-11-20 | 2014-11-20 | |
| PCT/US2015/061686 WO2016081772A1 (en) | 2014-11-20 | 2015-11-19 | Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017006655A true MX2017006655A (es) | 2018-03-12 |
Family
ID=54784026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017006655A MX2017006655A (es) | 2014-11-20 | 2015-11-19 | Metodos y composiciones que comprenden desmopresina en combinacion con un antagonista del receptor alfa-adrenergico. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10286033B2 (enExample) |
| EP (1) | EP3220942B1 (enExample) |
| JP (4) | JP2017535567A (enExample) |
| KR (2) | KR20170097045A (enExample) |
| CN (1) | CN106999538A (enExample) |
| AU (1) | AU2015349811B2 (enExample) |
| CA (1) | CA2967390A1 (enExample) |
| DK (1) | DK3220942T3 (enExample) |
| ES (1) | ES2923438T3 (enExample) |
| MX (1) | MX2017006655A (enExample) |
| WO (1) | WO2016081772A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105579057A (zh) | 2013-07-23 | 2016-05-11 | 阿勒根公司 | 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物 |
| WO2024211393A2 (en) * | 2023-04-04 | 2024-10-10 | Tulex Pharmaceuticals Inc. | Desmopressin oral compositions |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH495957A (de) | 1966-09-15 | 1970-09-15 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US4316893A (en) | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| IL101243A (en) | 1991-03-20 | 1999-12-22 | Merck & Co Inc | Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| AU751182B2 (en) * | 1997-12-02 | 2002-08-08 | Archimedes Development Limited | Compositions for nasal administration |
| US7335186B2 (en) | 1998-03-13 | 2008-02-26 | Alexander George Brian O'Neil | Patient controlled drug delivery device |
| US6558695B2 (en) | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
| AT409081B (de) * | 2000-02-16 | 2002-05-27 | Gebro Pharma Gmbh | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung |
| ES2705729T3 (es) | 2000-11-30 | 2019-03-26 | Valeritas Inc | Sistemas de suministro y medición de fluidos |
| US7244703B2 (en) | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
| US20030060513A1 (en) * | 2001-09-27 | 2003-03-27 | Arneric Stephen P. | Pharmaceutical composition |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
| CA2503570C (en) | 2002-11-07 | 2011-04-19 | Yamanouchi Pharmaceutical Co., Ltd. | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
| EP1689419A4 (en) * | 2003-11-10 | 2009-01-14 | Reprise Biopharmaceutics Llc | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW DOSAGE DESMOPRESSIN |
| ES2348303T3 (es) | 2003-12-08 | 2010-12-02 | Cpex Pharmaceuticals, Inc. | Composiciones farmacauticas y procedimientos de tratamiento con insulina. |
| DE102005016981A1 (de) * | 2005-04-13 | 2006-10-19 | Bayer Healthcare Ag | Kombination zur Therapie bei benigner Prostatahyperplasie |
| CA2633570A1 (en) | 2005-12-21 | 2007-06-28 | Pfizer Products Inc. | Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor |
| JPWO2007083640A1 (ja) | 2006-01-18 | 2009-06-11 | 杏林製薬株式会社 | 頻尿及び尿失禁の予防又は治療剤 |
| PL2014305T3 (pl) * | 2006-04-21 | 2018-02-28 | Toko Yakuhin Kogyo Kabushiki Kaisha | Preparat do rozpylania typu żelowego klejący się do skóry/błony śluzowej i układ podawania stosujący preparat |
| CA2695634C (en) * | 2007-08-06 | 2018-01-23 | Serenity Pharmaceuticals Corporation | Methods and devices for desmopressin drug delivery |
| CN101648017A (zh) * | 2008-08-12 | 2010-02-17 | 许洁 | 用于治疗泌尿生殖系统及下尿路疾病的联合药物组合物 |
| WO2010028211A1 (en) * | 2008-09-04 | 2010-03-11 | Rozmanith Anthony I | Health care |
| WO2010075327A1 (en) | 2008-12-22 | 2010-07-01 | Serenity Pharmaceuticals Corporation | Desmopressin composition |
| PT2381923T (pt) | 2008-12-22 | 2018-11-13 | Serenity Pharmaceuticals Llc | Administração intranasal de desmopressina |
| CN102647993A (zh) * | 2009-06-18 | 2012-08-22 | 阿勒根公司 | 安全的去氨加压素给药 |
| IN2012DN02782A (enExample) | 2009-10-07 | 2015-09-18 | Merck Sharp & Dohme | |
| US9119878B2 (en) * | 2010-07-08 | 2015-09-01 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| ES2634669T3 (es) * | 2011-02-08 | 2017-09-28 | Halozyme, Inc. | Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata |
| CN107569690A (zh) * | 2012-01-04 | 2018-01-12 | 韦尔斯利医药有限公司 | 用于缓解尿频的延长释放制剂及其使用方法 |
| WO2013142197A1 (en) * | 2012-03-19 | 2013-09-26 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| TW201422254A (zh) * | 2012-11-21 | 2014-06-16 | Ferring Bv | 用於速釋及延釋的組成物 |
| JP2016525147A (ja) * | 2013-07-23 | 2016-08-22 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ５−α還元酵素阻害剤と組み合わせたデスモプレシンを含む方法及び組成物 |
| CN105579057A (zh) | 2013-07-23 | 2016-05-11 | 阿勒根公司 | 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物 |
| MX2016002705A (es) * | 2013-09-03 | 2016-09-06 | G2B Pharma Inc | Formulacion intranasal para el tratamiento por reanimacion cardiopulmonar (rcp), mantenimiento cardiaco vital (cls), de anafilaxia y/o reacciones anafilactoides. |
| JP2014177491A (ja) * | 2014-06-26 | 2014-09-25 | Allergan Inc | 低用量デスモプレシンを含有する医薬組成物 |
-
2015
- 2015-11-19 JP JP2017527366A patent/JP2017535567A/ja active Pending
- 2015-11-19 AU AU2015349811A patent/AU2015349811B2/en not_active Ceased
- 2015-11-19 KR KR1020177016896A patent/KR20170097045A/ko not_active Ceased
- 2015-11-19 ES ES15805360T patent/ES2923438T3/es active Active
- 2015-11-19 KR KR1020247000547A patent/KR20240010751A/ko not_active Ceased
- 2015-11-19 MX MX2017006655A patent/MX2017006655A/es unknown
- 2015-11-19 DK DK15805360.3T patent/DK3220942T3/da active
- 2015-11-19 CN CN201580062683.6A patent/CN106999538A/zh active Pending
- 2015-11-19 WO PCT/US2015/061686 patent/WO2016081772A1/en not_active Ceased
- 2015-11-19 CA CA2967390A patent/CA2967390A1/en active Pending
- 2015-11-19 US US15/528,224 patent/US10286033B2/en active Active
- 2015-11-19 EP EP15805360.3A patent/EP3220942B1/en active Active
-
2020
- 2020-03-05 JP JP2020037385A patent/JP2020097632A/ja not_active Withdrawn
-
2022
- 2022-04-20 JP JP2022069213A patent/JP2022095948A/ja active Pending
-
2024
- 2024-08-13 JP JP2024134846A patent/JP2024161452A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN106999538A (zh) | 2017-08-01 |
| JP2020097632A (ja) | 2020-06-25 |
| JP2022095948A (ja) | 2022-06-28 |
| CA2967390A1 (en) | 2016-05-26 |
| KR20170097045A (ko) | 2017-08-25 |
| US10286033B2 (en) | 2019-05-14 |
| US20170319646A1 (en) | 2017-11-09 |
| EP3220942A1 (en) | 2017-09-27 |
| DK3220942T3 (da) | 2022-07-18 |
| WO2016081772A1 (en) | 2016-05-26 |
| KR20240010751A (ko) | 2024-01-24 |
| ES2923438T3 (es) | 2022-09-27 |
| JP2024161452A (ja) | 2024-11-19 |
| AU2015349811A1 (en) | 2017-07-06 |
| EP3220942B1 (en) | 2022-04-27 |
| JP2017535567A (ja) | 2017-11-30 |
| AU2015349811B2 (en) | 2021-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259660B (en) | Apelin receptor agonists and methods of use | |
| IL261721A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| PH12017500877B1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
| IL251066B (en) | Preparations and methods for the treatment of metabolic disorders | |
| ZA201700311B (en) | Compositions and methods of use for treating metabolic disorders | |
| CA3244408A1 (en) | Therapeutic compositions, combinations, and methods of use | |
| NZ730123A (en) | Processes and intermediates in the preparation of c5ar antagonists | |
| MY176855A (en) | Anti-jagged1 antibodies and methods of use | |
| ZA201701909B (en) | Trichoderma compositions and methods of use | |
| ZA201902781B (en) | Compositions and methods for the treatment of xerostomia | |
| MX2016001030A (es) | Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico. | |
| PT4101454T (pt) | Composições para utilização no tratamento da hipertensão | |
| IL271464A (en) | Nk-1 antagonist compositions and methods for use in treating depression | |
| EP3509612A4 (en) | CXCR4 ANTAGONISTS AND METHOD OF USE | |
| EP3304041A4 (en) | Methods of assessing cellular breast samples and compositions for use in practicing the same | |
| PT3719021T (pt) | Inibidores da cinase 1 associada a adaptador, composições compreendendo estes, e métodos da sua utilização | |
| PT3724196T (pt) | Azetidina di-hidrotienopiridinas substituídas e a sua utilização como inibidores de fosfodiesterase | |
| GB2581876B (en) | Compositions for use in the treatment of endometrial disorder | |
| IL257452B (en) | Methods and compositions for the treatment of cytoplasmic glycogen storage disorders | |
| GEP201706795B (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
| MX2017006655A (es) | Metodos y composiciones que comprenden desmopresina en combinacion con un antagonista del receptor alfa-adrenergico. | |
| MX2016001032A (es) | Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa. | |
| NZ744340A (en) | Anti-jagged1 antibodies and methods of use |